The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for the following active substances in the context of a so-called open house procedure:

Mebeverin (A03AA04)

Fluorouracil mono, cream only (D11AF05)

Rotigotine (N04BC09)

Ranolazin (C01EB18)

Teriflunomid (L04AA31)

Nilotinib (L01EA03)

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances mentioned.

The earliest start date of the contract is 01.09.2023. Based on this, the contract period is a maximum of 24 months.

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances mentioned.

The earliest start date of the contract is 01.09.2023. Based on this, the contract period is a maximum of 24 months.